Publication Name	World Journal of Respirology
Manuscript ID	22368
Country	Portugal

Received	2015-08-27 08:21
Peer-Review Started	2015-08-31 14:42
First Decision by Editorial Office Director
Return for Revision	2015-10-19 01:38
Revised
Publication Fee Transferred
Second Decision by Editor	2016-06-12 10:11
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2016-06-29 09:54
Articles in Press	2016-06-29 09:54
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-12 11:55
Publish the Manuscript Online	2016-07-19 08:57

ISSN	2218-6255 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Frontier
Article Title	New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer
Manuscript Source	Invited Manuscript
All Author List	Joana Espiga Macedo
Funding Agency and Grant Number
Corresponding Author	Joana Espiga Macedo, MD, Consultant of Medical Oncology, Department of Medical Oncology, Centro Hospitalar de Entre Douro e Vouga, Rua Dr. Cândido de Pinho, 4520-211 Santa Maria Da Feira, Portugal. joanamacedo@hotmail.com
Key Words	Epidermal growth factor receptor-tyrosine kinase inhibitors; Clonal evolution; Non-small cell lung cancer; Acquired resistance
Core Tip	Dramatic changes have occurred in the last decades, concerning the treatment of lung cancer. The knowledge of clinical, pathological and molecular pathways has allowed sub-classifying non-small cell lung cancer (NSCLC), to a point where it has never been reached. The determination of activating mutations of epidermal growth factor receptor (EGFR) has permitted the use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib in first, second and maintenance setting. However, acquired resistance develops at some stage of the disease, and second generation TKIs have been developed, but with similar results to traditional chemotherapy. With the arrival of third generation TKIs, a selective target mutational personalized therapy has accomplished better response rates, with a lower toxicity profile in phase Ⅰ clinical trials. The question is should NSCLC patients with exon 19del and L858R point mutation in exon 21 be treated differently, once the driver oncogene is known? On the other hand, if patients with acquired resistance with EGFR T790M, should they also be treated targeting this predominant clone?
Publish Date	2016-07-19 08:57
Citation	Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62
URL	http://www.wjgnet.com/2218-6255/full/v6/i2/57.htm
DOI	http://dx.doi.org/10.5320/wjr.v6.i2.57

Full Article (PDF)	WJR-6-57.pdf
Full Article (Word)	WJR-6-57.doc